超4.75亿美元！iTeos Therapeutics宣布关门后被收购

Medaverse2025-07-21

7月21日，iTeos Therapeutics（NASDAQ：ITOS）宣布其已签订最终合并协议，根据该协议Concentra Biosciences，LLC（“Concentra”）将以每股10.047美元的现金收购iTeos，每股iTeos普通股每股面值0.001美元（“iTeos普通股”），外加一项不可转让或有价值权（“CVR”），该权利获得：（i）iTeos期末净现金的100%，超过...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2553408163?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-21 21:40","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2553408163","market":"us","top_or_hot":-1,"title":"超4.75亿美元！iTeos Therapeutics宣布关门后被收购","media":"Medaverse","content":"<div>\n<p>7月21日，iTeos Therapeutics（NASDAQ：ITOS）宣布其已签订最终合并协议，根据该协议Concentra Biosciences，LLC（“Concentra”）将以每股10.047美元的现金收购iTeos，每股iTeos普通股每股面值0.001美元（“iTeos普通股”），外加一项不可转让或有价值权（“CVR”），该权利获得：（i）iTeos期末净现金的100%，超过...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721225241a6b86a4b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>超4.75亿美元！iTeos Therapeutics宣布关门后被收购</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n超4.75亿美元！iTeos Therapeutics宣布关门后被收购\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-21 21:40 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721225241a6b86a4b&s=b><strong>Medaverse</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月21日，iTeos Therapeutics（NASDAQ：ITOS）宣布其已签订最终合并协议，根据该协议Concentra Biosciences，LLC（“Concentra”）将以每股10.047美元的现金收购iTeos，每股iTeos普通股每股面值0.001美元（“iTeos普通股”），外加一项不可转让或有价值权（“CVR”），该权利获得：（i）iTeos期末净现金的100%，超过...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721225241a6b86a4b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721225241a6b86a4b&s=b","article_id":"2553408163","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721225241a6b86a4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2553408163","pubTimestamp":1753105206,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"在iTeos管理层、法律和财务顾问的协助下进行了战略审查后，iTeos董事会一致决定，Concentra的收购符合所有iTeos股东的最佳利益，并批准了合并协议和相关交易。要约结束后，iTeos将立即被Concentra收购，要约中未投标的所有剩余股份，除iTeos、Concentra或其子公司或适当要求评估的持有人直接或间接拥有的股份外，将转换为每股iTeos普通股收取与要约中规定的相同要约对价的权利。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药","ITOS":"iTeos Therapeutics","GSK":"葛兰素史克","BK4539":"次新股"},"translate_title":"Over $475 million! iTeos Therapeutics Acquired After Announcing Closure","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"GSK":0.9,"ITOS":1},"content_text":"7月21日，iTeos Therapeutics（NASDAQ：ITOS）宣布其已签订最终合并协议，根据该协议Concentra Biosciences，LLC（“Concentra”）将以每股10.047美元的现金收购iTeos，每股iTeos普通股每股面值0.001美元（“iTeos普通股”），外加一项不可转让或有价值权（“CVR”），该权利获得：（i）iTeos期末净现金的100%，超过4.75亿美元；以及（ii）交割后六个月内处置iTeos某些候选产品所收到的任何净收益的80%（现金和CVR对价，“要约对价”）。在iTeos管理层、法律和财务顾问的协助下进行了战略审查后，iTeos董事会一致决定，Concentra的收购符合所有iTeos股东的最佳利益，并批准了合并协议和相关交易。根据合并协议的条款，Concentra将于2025年8月1日前开始要约收购，以收购iTeos普通股的所有已发行股份作为要约对价。收购要约的完成受某些条件的约束，包括出售一定数量的iTeos普通股，这些股份与Concentra或其附属公司拥有的iTeos普通股股份一起，至少占已发行股份总数的大部分，交割时至少有4.75亿美元现金（扣除交易成本和其他负债）的可用性，以及其他惯例交割条件。要约结束后，iTeos将立即被Concentra收购，要约中未投标的所有剩余股份，除iTeos、Concentra或其子公司或适当要求评估的持有人直接或间接拥有的股份外，将转换为每股iTeos普通股收取与要约中规定的相同要约对价的权利。根据惯例成交条件的满足或放弃，该交易预计将于2025年第三季度完成。5月13日，葛兰素史克（GSK）宣布停止开发TIGIT抗体药物belrestotug。仅在终止与GSK合作的TIGIT候选药物两周后，5月28日，GSK合作伙伴——比利时药企iTeos公司决定逐步停止运营、出售资产，并尽可能将其6亿多美元的现金储备返还给投资者。面对其TIGIT抗体药物令人失望的数据，GSK退出TIGIT研发竞赛，这延续了该领域一连串的退出潮。此前退出的包括百时美施贵宝、诺华、罗氏制药、默沙东、君实生物、百济神州等。TIGIT靶点曾被视为继PD-1/PD-L1之后的重要免疫检查点，但多项III期试验显示，其与PD-1抑制剂联用未能显著提升患者生存获益。关注下方公众号，带你看世界!","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2553408163","isCrawlerRequest":true}